Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.49 USD | -0.57% | +6.64% | +41.40% |
Sales 2024 * | 42.22M 3.52B | Sales 2025 * | 114M 9.48B | Capitalization | 1.79B 149B |
---|---|---|---|---|---|
Net income 2024 * | -318M -26.51B | Net income 2025 * | -361M -30.1B | EV / Sales 2024 * | 40.7 x |
Net cash position 2024 * | 68.82M 5.74B | Net Debt 2025 * | 36.47M 3.04B | EV / Sales 2025 * | 16 x |
P/E ratio 2024 * |
-5.75
x | P/E ratio 2025 * |
-5.35
x | Employees | 385 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.35% |
Latest transcript on Agios Pharmaceuticals, Inc.
1 day | -0.57% | ||
1 week | +6.64% | ||
Current month | +7.69% | ||
1 month | +8.14% | ||
3 months | +34.69% | ||
6 months | +57.69% | ||
Current year | +41.40% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Goff
CEO | Chief Executive Officer | 55 | 08/22/08 |
Cecilia Jones
DFI | Director of Finance/CFO | 49 | 26/22/26 |
Jacqualyn Fouse
CHM | Chairman | 62 | 05/17/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Capello
BRD | Director/Board Member | 69 | 01/23/01 |
Director/Board Member | 64 | 09/14/09 | |
May Kin Ho
BRD | Director/Board Member | 71 | 23/15/23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.52% | 1 M€ | -5.79% | - | |
0.16% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 31.49 | -0.57% | 419,310 |
25/24/25 | 31.67 | 0.00% | 721,957 |
24/24/24 | 31.67 | -0.44% | 643,302 |
23/24/23 | 31.81 | +5.30% | 1,225,395 |
22/24/22 | 30.21 | +2.30% | 861,755 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.40% | 1.79B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- AGIO Stock